prednisolone has been researched along with Cacosmia in 20 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyposmia and anosmia are common in COVID-19." | 3.11 | COCOS trial: ( Boek, WM; Boesveldt, S; Kamalski, DMA; Schepens, EJA; Stegeman, I; Stokroos, RJ, 2022) |
| "Prednisolone has been suggested as a treatment for olfactory disorders after COVID-19, but evidence is scarce." | 3.11 | Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial. ( Blijleven, EE; Boek, WM; Boesveldt, S; Kamalski, DMA; Schepens, EJA; Stegeman, I; Stokroos, RJ, 2022) |
| "Treatment with prednisolone successfully prevented inflammatory infiltration over significant regions of the OE." | 1.37 | The role of TNF-α in inflammatory olfactory loss. ( Lane, AP; May, LA; Sultan, B, 2011) |
| "Anemia, hyperimmunoglobulinemia with hypo-albuminemia (no M-protein) and liver dysfunction were found." | 1.28 | Successful treatment of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia. ( Fujiwara, Y; Ohnishi, K; Tanabe, N; Tanaka, M; Uchida, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schepens, EJA | 4 |
| Boek, WM | 4 |
| Boesveldt, S | 4 |
| Stegeman, I | 4 |
| Stokroos, RJ | 4 |
| Kamalski, DMA | 4 |
| Blijleven, EE | 3 |
| Paksoy, ZB | 1 |
| Cayonu, M | 1 |
| Yucel, C | 1 |
| Turhan, T | 1 |
| Jiang, RS | 2 |
| Twu, CW | 1 |
| Liang, KL | 2 |
| Hegde, V | 1 |
| Mitry, D | 1 |
| Snead, D | 1 |
| Ahluwalia, H | 1 |
| Seo, BS | 1 |
| Lee, HJ | 1 |
| Mo, JH | 1 |
| Lee, CH | 1 |
| Rhee, CS | 1 |
| Kim, JW | 1 |
| Wu, SH | 1 |
| Shiao, JY | 1 |
| Hsin, CH | 1 |
| Su, MC | 1 |
| Sultan, B | 1 |
| May, LA | 1 |
| Lane, AP | 1 |
| Lee, SJ | 1 |
| Yoo, HJ | 1 |
| Park, SW | 1 |
| Choi, MG | 1 |
| Heilmann, S | 1 |
| Just, T | 1 |
| Göktas, O | 1 |
| Hauswald, B | 1 |
| Hüttenbrink, KB | 1 |
| Hummel, T | 1 |
| Jankowski, R | 2 |
| Bonfils, P | 4 |
| Avan, P | 1 |
| Malinvaud, D | 2 |
| Ikeda, K | 2 |
| Sakurada, T | 2 |
| Suzaki, Y | 1 |
| Takasaka, T | 2 |
| Okitsu, T | 1 |
| Yoshida, S | 1 |
| Faulcon, P | 1 |
| Biacabe, B | 1 |
| Werner, A | 1 |
| Ohashi, H | 1 |
| Itoh, M | 1 |
| Ogawa, N | 1 |
| Sudo, Y | 1 |
| Endo, S | 1 |
| Okugawa, T | 1 |
| Ito, H | 1 |
| Mineta, H | 1 |
| Nozue, M | 1 |
| Tanabe, N | 1 |
| Uchida, T | 1 |
| Fujiwara, Y | 1 |
| Ohnishi, K | 1 |
| Tanaka, M | 1 |
| Shiba, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)[NCT05216614] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-14 | Withdrawn (stopped due to Unable to obtain investigational product) | ||
| Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients[NCT04484493] | Phase 3 | 100 participants (Actual) | Interventional | 2020-08-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prednisolone and Cacosmia
| Article | Year |
|---|---|
[Smell dysfunction in nasal and paranasal sinus disease: a review of the literature (I)].
Topics: Anti-Inflammatory Agents; Beclomethasone; Chronic Disease; Humans; Nasal Polyps; Olfaction Disorders | 2001 |
8 trials available for prednisolone and Cacosmia
| Article | Year |
|---|---|
COCOS trial:
Topics: Adrenal Cortex Hormones; Anosmia; COVID-19; COVID-19 Testing; Humans; Olfaction Disorders; Prednisol | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; COVID-19; COVID-19 Drug Treatment; Humans; Olfaction Disorders; Prednisolone; Quality of | 2022 |
Medical treatment of traumatic anosmia.
Topics: Adult; Aged; Craniocerebral Trauma; Drug Therapy, Combination; Female; Glucocorticoids; Gluconates; | 2015 |
Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Ch | 2009 |
Steroid treatment of posttraumatic anosmia.
Topics: Adolescent; Adult; Aged; Brain Injuries; Cohort Studies; Dose-Response Relationship, Drug; Drug Admi | 2010 |
[Effects of systemic or topical administration of corticosteroids and vitamin B in patients with olfactory loss].
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Ma | 2004 |
Nasal surgery: evidence of efficacy. Evidence on efficacy in nasal surgery. Surgical management of nasal polyposis.
Topics: Anti-Inflammatory Agents; Budesonide; Combined Modality Therapy; Humans; Nasal Obstruction; Nasal Po | 2004 |
Anosmia following head trauma: preliminary study of steroid treatment.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Child; Craniocerebral Trauma; Female; Humans; Mal | 1995 |
11 other studies available for prednisolone and Cacosmia
| Article | Year |
|---|---|
The treatment efficacy of nasal polyposis on olfactory functions, clinical scoring systems and inflammation markers.
Topics: Adult; Biomarkers; Chemokines, CC; Endoscopy; Endothelins; Female; Follow-Up Studies; Humans; Inflam | 2019 |
Bilateral infiltrative orbital disease: is it chemically induced?
Topics: Aged; Asthma; Exophthalmos; Functional Laterality; Glucocorticoids; Humans; Male; Occupational Disea | 2008 |
The role of TNF-α in inflammatory olfactory loss.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Humans; Mice; Mice, Transgenic | 2011 |
A case of cystic lymphocytic hypophysitis with cacosmia and hypopituitarism.
Topics: Adult; Cysts; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Hypopituita | 2004 |
Influence of allergy on the symptoms and treatment of nasal polyposis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Beclomethasone; Bronchial Provocation Test | 2006 |
Influence of allergy in patients with nasal polyposis after endoscopic sinus surgery.
Topics: Adult; Asthma; Beclomethasone; Bronchial Hyperreactivity; Bronchial Provocation Tests; Combined Moda | 2008 |
Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease.
Topics: Administration, Intranasal; Adult; Anti-Inflammatory Agents; Beclomethasone; Chronic Disease; Female | 1995 |
[Contribution of corticosteroid treatment in neurosensorial anosomia: a series of 62 patients].
Topics: Adult; Aged; Aged, 80 and over; Female; Glucocorticoids; Humans; Male; Middle Aged; Olfaction Disord | 2000 |
Wegener's granulomatosis in a patient with a rheumatoid arthritis.
Topics: Adult; Antigen-Antibody Complex; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumato | 1992 |
Successful treatment of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia.
Topics: Castleman Disease; Edema; Eyelid Diseases; Humans; Hypergammaglobulinemia; Lymphatic Diseases; Male; | 1992 |
[Use of corticoid in the field of otolaryngology. I. Anosmia and decreased sense of smell].
Topics: Adult; Humans; Middle Aged; Olfaction Disorders; Prednisolone; Smell | 1970 |